Can bacitracin and corticotropin be used together?

Yes, they could theoretically be used together since they work via different mechanisms and routes. A patient might receive bacitracin topically for a minor wound while also taking corticotropin for an autoimmune condition. However, there's no synergistic benefit, and such use would be determined by the patient's specific medical needs, not by any intended interaction.

Which peptide is more commonly prescribed?

Bacitracin is far more commonly used in everyday practice because it's available over-the-counter in the US and applied topically to minor wounds. Corticotropin is a specialized prescription medication used primarily in hospital or specialist settings for severe autoimmune conditions, making it less frequently prescribed overall.

Is bacitracin better than corticotropin for infections?

Bacitracin is designed for topical infection prevention and treatment of minor bacterial skin infections. Corticotropin is not an antimicrobial and wouldn't be used for infections—it's used to suppress immune responses in autoimmune disease. They're tools for different problems.

Why isn't corticotropin approved in Europe?

The EMA has not authorized corticotropin, reflecting regulatory decision-making that may include manufacturing, demand, or clinical prioritization factors. The reasons are not publicly documented in detail, but approval status varies across therapeutic peptides for various regulatory and commercial reasons.

Can I use bacitracin instead of corticotropin for inflammation?

No. Bacitracin has no systemic anti-inflammatory mechanism and is not absorbed systemically. For inflammatory or autoimmune conditions, it would be ineffective. Only corticotropin has the hormonal mechanism required for systemic immunomodulation.

Bacitracin vs Corticotropin: Key Differences & Uses

Bacitracin and Corticotropin are both FDA-approved peptide therapeutics, but they work in fundamentally different ways. Bacitracin is a topical antibiotic peptide that kills bacteria by disrupting cell wall synthesis, while Corticotropin is a hormone that stimulates cortisol production to modulate inflammation and immune response. The choice between them depends entirely on the condition being treated—they're not interchangeable alternatives, but rather tools for different medical problems. Understanding their distinct mechanisms, regulatory standing, and evidence bases helps clarify when each belongs in a clinical toolkit.

What Is Bacitracin?

Backtracin is a cyclic peptide antibiotic derived from the bacterium Bacillus subtilis. It's been FDA-approved since the 1950s and remains a cornerstone of topical antimicrobial therapy. The compound works by inhibiting bacterial cell wall synthesis, making it bactericidal—it actively kills bacteria rather than merely slowing their growth.

The peptide is available in multiple formulations: ointments (often combined with neomycin and polymyxin B in triple-antibiotic ointments), powders, and solutions. Because it's topical and poorly absorbed systemically, it's used primarily for minor wound care, skin infections, and eye infections. Bacitracin has a narrow spectrum, primarily effective against gram-positive bacteria and some gram-negative organisms, but notably ineffective against Pseudomonas aeruginosa and most gram-negative rods.

Clinical Evidence for Bacitracin

Backtracin has accumulated over 40 clinical trials documenting its safety and efficacy. Research shows it's effective in preventing infection in minor lacerations and surgical wounds, with low rates of systemic adverse effects due to minimal systemic absorption. The peptide is particularly valued in wound care because it has a long safety record and low sensitization rates compared to older topical antibiotics.

Regulatory Status: Bacitracin

United States: FDA-approved (available over-the-counter)
European Union: Not authorised by the EMA
Canada: Health Canada-approved

What Is Corticotropin?

Corticotropin (also called adrenocorticotropic hormone or ACTH) is a 39-amino acid peptide hormone naturally secreted by the anterior pituitary gland. It acts as a signaling molecule that stimulates the adrenal cortex to produce and release cortisol and other glucocorticoids. Unlike bacitracin's direct antibacterial action, corticotropin works by triggering a systemic hormonal cascade.

The pharmaceutical form is typically synthetic or derived from animal pituitary tissue, and it's administered via intramuscular or intravenous injection. Corticotropin has immunosuppressive and anti-inflammatory effects, making it useful in conditions where excessive inflammation or autoimmune activation is the problem.

Clinical Evidence for Corticotropin

Corticotropin has the most robust clinical trial portfolio of the two, with 185 clinical trials registered exploring its use across multiple indications. Meta-analyses and systematic reviews document its efficacy in infantile spasms (West syndrome), lupus nephritis, and certain autoimmune conditions. The peptide's mechanism—stimulating endogenous cortisol production rather than directly delivering glucocorticoids—may offer advantages in some clinical contexts, though evidence remains mixed and ongoing.

Regulatory Status: Corticotropin

United States: FDA-approved (prescription required)
European Union: Not authorised by the EMA
Canada: Not approved by Health Canada

Key Mechanistic Differences

Bacitracin is a direct-acting antimicrobial. It binds to lipid carriers in bacterial cell membranes and prevents cell wall synthesis. The effect is local (topical application) and organism-specific (antibacterial). There's no systemic mechanism of action.

Corticotropin is an endocrine signaling molecule. It travels through the bloodstream, binds to melanocortin receptors on adrenocortical cells, and triggers a hormone cascade. The effect is systemic and immunomodulatory. It requires intact hypothalamic-pituitary-adrenal (HPA) axis function to work.

This fundamental difference means:

Bacitracin is used for infections; Corticotropin for inflammation and autoimmunity
Bacitracin requires local application; Corticotropin requires systemic administration
Bacitracin has a narrow therapeutic window (topical dosing); Corticotropin has complex dose-response relationships tied to HPA axis sensitivity

Clinical Applications and Indications

Bacitracin Use Cases

Minor cuts, scrapes, and abrasions (prevention of infection)
Surgical wound care and post-operative prophylaxis
Ophthalmologic infections (bacitracin eye ointment)
Minor burns
Impetigo and other superficial skin infections (topical adjunct)

Backtracin shines in infection prevention for minor wounds. Its low systemic absorption makes it ideal for populations where systemic antibiotics might carry risk (infants, pregnant patients, those with drug sensitivities).

Corticotropin Use Cases

Infantile spasms (West syndrome)
Lupus nephritis and other lupus manifestations
Pemphigus vulgaris
Certain autoimmune vasculitides
Adrenal insufficiency (though less common now than synthetic glucocorticoids)
Inflammatory bowel disease (investigational in some contexts)

Corticotropin is typically reserved for conditions where glucocorticoid therapy is indicated but where the pharmacology of stimulating endogenous cortisol production may offer clinical advantage over exogenous steroid administration.

Adverse Effects and Safety Profiles

Bacitracin Safety

Bacitracin is well-tolerated when used topically, with the most common adverse effect being contact dermatitis or local sensitization (occurring in 1–2% of users). Systemic absorption is minimal, so systemic toxicity is rare. Nephrotoxicity has been documented with parenteral use (now largely historical), but topical application carries negligible risk.

Corticotropin Safety

Corticotropin's adverse effect profile mirrors systemic glucocorticoid therapy: hypertension, hyperglycemia, osteoporosis risk with long-term use, immunosuppression, mood disturbances, and HPA axis suppression. Because corticotropin stimulates endogenous cortisol rather than directly providing exogenous steroids, some experts hypothesize reduced suppression of the HPA axis, but this remains debated in the literature. Hypersensitivity reactions to animal-derived ACTH preparations are possible but uncommon with synthetic formulations.

Regulatory Differences and Access

Bacitracin's approval in the US and Canada but not the EU reflects historical regulatory divergence—the EMA has not authorized it, likely due to evolving antimicrobial stewardship policies and availability of alternative topical agents.

Corticotropin's approval only in the US (among these three jurisdictions) is noteworthy. The lack of EMA or Health Canada authorization may reflect lower demand outside the US, manufacturing considerations, or regulatory pathway decisions by sponsoring companies. In the US, corticotropin remains available but typically via specialty pharmacies, and prescribing requires careful monitoring.

Who Each Is Best Suited For

Choose Bacitracin If:

Managing minor wounds, cuts, or surgical sites requiring infection prevention
Patient has systemic antibiotic sensitivities or contraindications
Topical application is feasible and preferred
Cost and over-the-counter availability matter
No signs of systemic infection (bacitracin is not a systemic treatment)

Choose Corticotropin If:

Treating an autoimmune or severe inflammatory condition requiring immunosuppression
Patient has infantile spasms or another indication where corticotropin has specific evidence
Glucocorticoid therapy is indicated and endogenous stimulation may be advantageous
Patient can tolerate systemic hormone therapy and monitoring
Access and specialist oversight are available

Bottom Line

These compounds aren't competing for the same clinical role. Bacitracin is a topical antibiotic for wound care; Corticotropin is a systemic immunomodulator for autoimmune and inflammatory disease. Comparing them is like comparing a bandage to an immunosuppressant—they address entirely different problems. Understanding their distinct mechanisms, evidence bases, and regulatory status clarifies when each belongs in clinical practice. For questions about which is appropriate for a specific condition, consultation with a healthcare provider is essential.

Related Compounds

If you're exploring peptide therapeutics, you may also want to understand how these compare to related compounds:

Polymyxin B: Another peptide antibiotic, often combined with bacitracin in topical formulations
Desmopressin: A peptide hormone with systemic effects, offering comparison to how peptide hormones work
Cosyntropin: A synthetic ACTH analogue with a similar mechanism to corticotropin but shorter duration

For deeper context on peptide biology, explore our glossary entries on peptide hormones and antimicrobial peptides.

Bacitracin vs Corticotropin: Understanding Two Different Peptides